Literature DB >> 25683276

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial.

B D Westenbrink1, M Alings, S J Connolly, J Eikelboom, M D Ezekowitz, J Oldgren, S Yang, J Pongue, S Yusuf, L Wallentin, W H van Gilst.   

Abstract

BACKGROUND: Anemia may predispose to thromboembolic events or bleeding in anticoagulated patients with atrial fibrillation (AF).
OBJECTIVES: To investigate whether anemia is associated with thromboembolic events and bleeding in patients with AF. PATIENTS AND METHODS: We retrospectively analyzed the RE-LY trial database, which randomized 18 113 patients with AF and a risk of stroke to receive dabigatran or warfarin for a median follow-up of 2 years. Cox regression analysis was used to determine whether anemia predicted cardiovascular events and bleeding complications in these patients.
RESULTS: Anemia was present in 12% of the population at baseline, and the presence of anemia was associated with a higher risk of thromboembolic cardiovascular events, including the composite endpoint of all-cause mortality or myocardial infarction (adjusted hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.32-1.71) and the primary RE-LY outcome of stroke or systemic embolism (adjusted HR 1.41, 95% CI 1.12-1.78). Anemia was also associated with a higher risk of major bleeding complications (adjusted HR 2.14, 95% CI 1.87-2.46) and discontinuation of anticoagulants (adjusted HR 1.40, 95% CI 1.28-1.79). The association between anemia and outcome was similar irrespective of cardiovascular comorbidities, randomized treatment allocation, or prior use of warfarin. The incidence of events was lower in patients with transient anemia than in patients in whom anemia was sustained (adjusted HR 0.66, 95% CI 0.49-0.91).
CONCLUSIONS: Anemia is associated with an increased risk of thromboembolic events, bleeding complications and mortality in anticoagulated patients with AF. These findings suggest that patients with anemia should be monitored closely during all types of anticoagulant treatment.
© 2015 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  anemia; anticoagulants; bleeding; mortality; thromboembolism

Mesh:

Year:  2015        PMID: 25683276     DOI: 10.1111/jth.12874

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  15 in total

1.  Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.

Authors:  Kathryn T Hall; Thorsten Kessler; Julie E Buring; Dani Passow; Howard D Sesso; Robert Y L Zee; Paul M Ridker; Daniel I Chasman; Heribert Schunkert
Journal:  Eur Heart J       Date:  2019-11-01       Impact factor: 29.983

Review 2.  Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia.

Authors:  Viktoria Kuhn; Lukas Diederich; T C Stevenson Keller; Christian M Kramer; Wiebke Lückstädt; Christina Panknin; Tatsiana Suvorava; Brant E Isakson; Malte Kelm; Miriam M Cortese-Krott
Journal:  Antioxid Redox Signal       Date:  2017-01-18       Impact factor: 8.401

3.  'Enemy within': an interesting cause for anemia during warfarin therapy for atrial fibrillation.

Authors:  Anita Ann Sunny; Josy Vallipalam; Balakrishnan Ramasamy; Rajesh Shankar Iyer
Journal:  BMJ Case Rep       Date:  2019-07-26

Review 4.  Anemia: An Independent Predictor Of Adverse Outcomes In Older Patients With Atrial Fibrillation.

Authors:  Ali N Ali; Nandkishor V Athavale; Ahmed H Abdelhafiz
Journal:  J Atr Fibrillation       Date:  2016-04-30

5.  Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.

Authors:  Amir Kuperman; Raquel López-Reyes; Lopez-Saez Juan Bosco; Alicia Lorenzo; Bascuñana José; Dominique Farge Bancel; María Alfonso; Marina Lumbierres; Galia Stemer; Manuel Monreal Bosch; Andrei Braester
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

6.  Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.

Authors:  Carmen Suárez Fernández; Suárez Fernández; Francesc Formiga; Miguel Camafort; María Cepeda Rodrigo; Jose Cepeda Rodrigo; Jesús Díez-Manglano; Antonio Pose Reino; Pose Reino; Gregorio Tiberio; Jose María Mostaza
Journal:  BMC Cardiovasc Disord       Date:  2015-11-04       Impact factor: 2.298

Review 7.  Prediction of New-Onset and Recurrent Atrial Fibrillation by Complete Blood Count Tests: A Comprehensive Systematic Review with Meta-Analysis.

Authors:  Alexander Weymann; Sadeq Ali-Hasan-Al-Saegh; Anton Sabashnikov; Aron-Frederik Popov; Seyed Jalil Mirhosseini; Tong Liu; Mohammadreza Lotfaliani; Michel Pompeu Barros de Oliveira Sá; William L L Baker; Senol Yavuz; Mohamed Zeriouh; Jae-Sik Jang; Hamidreza Dehghan; Lei Meng; Luca Testa; Fabrizio D'Ascenzo; Umberto Benedetto; Gary Tse; Luis Nombela-Franco; Pascal M Dohmen; Abhishek J Deshmukh; Cecilia Linde; Giuseppe Biondi-Zoccai; Gregg W Stone; Hugh Calkins; Integrated Meta-Analysis Of Cardiac Surgery And Cardiology-Group Imcsc-Group
Journal:  Med Sci Monit Basic Res       Date:  2017-05-12

8.  Optimal Choice of Pharmacological Therapy - Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation.

Authors:  Enisa Hodzic; Edin Begic; Sedina Zuhric; Azra Durak Nalbantic; Zijo Begic; Izet Masic
Journal:  Int J Prev Med       Date:  2019-05-17

9.  Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention.

Authors:  Barış Yaylak; Bernas Altıntaş; Kazım Serhan Özcan; Evliya Akdeniz; İlker Avcı; Gönül Zeren; Barış Şimşek; Can Yücel Karabay
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-12-11       Impact factor: 1.426

10.  Anaemia is associated with severe RBC dysfunction and a reduced circulating NO pool: vascular and cardiac eNOS are crucial for the adaptation to anaemia.

Authors:  Patricia Wischmann; Viktoria Kuhn; Tatsiana Suvorava; Johanna M Muessig; Jens W Fischer; Brant E Isakson; Sebastian M Haberkorn; Ulrich Flögel; Jürgen Schrader; Christian Jung; Miriam M Cortese-Krott; Gerd Heusch; Malte Kelm
Journal:  Basic Res Cardiol       Date:  2020-06-12       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.